Heart Test Laboratories, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Patent covers use of ai-ecg for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease patent covers use of ai-ecg for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease

Southlake, tx, april 02, 2024 (globe newswire) -- heart test laboratories, inc. d/b/a heartsciences  (nasdaq: hscs; hscsw) ("heartsciences" or the "company"), an artificial intelligence (ai)-powered medical technology company focused on transforming ecgs/ekgs to save lives through earlier detection of heart disease, today announced that chief executive officer andrew simpson is scheduled to present at the ld micro invitational xiv conference on tuesday april 9, 2024 at 5:00pm et at the sofitel new york. mr. simpson will also be hosting one-on-one meetings through the conference.

Data demonstrated the use of myovista wavecgtm for screening preoperative patients for lvdd can be recommended data demonstrated the use of myovista wavecgtm for screening preoperative patients for lvdd can be recommended

Southlake, tx, march 14, 2024 (globe newswire) -- heart test laboratories, inc. d/b/a heartsciences (nasdaq: hscs; hscsw) ("heartsciences" or the "company"), an artificial intelligence (ai)-powered medical technology company focused on transforming ecgs/ekgs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended january 31, 2024 and provided a business update.

Data demonstrated myovista ai-ecg model significantly outperformed nt-probnp and aric hf score, the conventional standards of care for stage b heart failure screening data demonstrated myovista ai-ecg model significantly outperformed nt-probnp and aric hf score, the conventional standards of care for stage b heart failure screening

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.

Heart Test Laboratories (NASDAQ: HSCS ) stock is falling hard on Wednesday after the medical technology company announced a secondary offering for its shares. Heart Test Laboratories notes that this is a resale of 34,684,859 shares of HSCS stock by a few shareholders.

Heart Test Laboratories (NASDAQ: HSCS ) stock is rising higher on Wednesday without any clear news from the maker of cardiovascular diagnostic devices. There have been no new press releases or filings with the Securities and Exchange Commission that explain why HSCS stock is rising higher today.

Heart Test Laboratories (NASDAQ: HSCS ) stock is on the move Thursday after announcing an agreement with the Icahn School of Medicine at Mount Sinai. This new agreement has Heart Test Laboratories' HeartSciences working with Icahn Mount Sinai to commercialize electrocardiographic artificial intelligence ( AI ) algorithms and assets.

Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 11:30 am ET.

Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc.  d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois. Mr. Simpson is scheduled to present on Wednesday, October 12th at 1:30 p.m.